Christine Baeder, Teva Pharmaceutical Industries Ltd.’s senior vice president and chief operating officer for US generics, was just elected chair of the Association of Accessible Medicines’ board of directors, giving her a commanding view of some of the most momentous events for the generic industry in the coming year, including the early implementation of the Inflation Reduction Act’s drug pricing provisions and the launch of biosimilars for the biggest Rx product in the world, Humira.
The Pink Sheet caught up with Baeder at the sidelines of the AAM’s annual meeting in Orlando on 14 February